DelveInsight’s “Hepatic Cirrhosis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Hepatic Cirrhosis, historical and forecasted epidemiology as well as the Hepatic Cirrhosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hepatic Cirrhosis market report provides current treatment practices, emerging drugs, Hepatic Cirrhosis market share of the individual therapies, and current and forecasted Hepatic Cirrhosis market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Hepatic Cirrhosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of opportunities. It assesses the underlying potential of the Hepatic Cirrhosis market.
Some of the key facts of the Hepatic Cirrhosis Market Report:
- According to a study by Michitaka et al. (2010), in Japan of 33,379 patients with Hepatic Cirrhosis included in this study, 62.4% were male, and 37.6% were female had hepatocellular carcinoma at the time of diagnosis with Hepatic Cirrhosis.
- According to The European Association for the Study of the Liver 2018, the prevalence of hepatitis C, for instance, is up to 50 times higher in people who inject drugs, compared to the general population, in European countries where data are available. Data on risk behaviors are limited for many countries, but the prevalence of injection drugs in Spain is 0.02%.
Key benefits of the Hepatic Cirrhosis Market report:
- The report covers the descriptive overview of Hepatic Cirrhosis, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the Hepatic Cirrhosis epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Hepatic Cirrhosis is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Hepatic Cirrhosis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Hepatic Cirrhosis market
Got queries? Click here to know more about the Hepatic Cirrhosis Market Landscape
Hepatic Cirrhosis Overview
Cirrhosis is characterized by fibrosis and nodule formation of the liver secondary to chronic injury, leading to alteration of the normal lobular organization of the liver. Various insults can injure the liver, including viral infections, toxins, hereditary conditions, or autoimmune processes. With each injury, the liver forms scar tissue (fibrosis), initially without losing its function. After a chronic injury, most of the liver tissue becomes fibrotic, leading to loss of function and the development of cirrhosis. Chronic liver diseases usually progress to cirrhosis. In the developed world, the most common causes of cirrhosis are hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH), while hepatitis B virus (HBV) and HCV are the most common causes in the developing world. Other causes of cirrhosis include autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver cirrhosis, and chronic right-sided heart failure. Diagnosis of PFIC is based on clinical manifestations, liver ultrasonography, cholangiography, genetic testing of liver and liver histology (biopsy), as well as on specific tests for excluding other causes of childhood cholestasis. MDR3 and BSEP liver immunostaining, and analysis of biliary lipid composition should help to select PFIC candidates in whom genotyping could be proposed to confirm the diagnosis. Treatment goals are preventing cirrhosis, decompensation, and death.
Hepatic Cirrhosis Market Epidemiological Insights:
- According to a study by Scaglione et al. (2015), the prevalence of cirrhosis in the United States was approximately 0.27%, corresponding to 633,323 adults over the age of 18.
- As per a study by Fleming et al. (2008), the prevalence of cirrhosis was an estimated 76.3 per 100,000 population aged over 25 in the UK.
- According to an article by Scaglione et al. (2015), there was a prevalence rate of 0.0014% of
- Hepatic Cirrhosis in the 75 years old in the United States
- 5 Recently, in a large secondary care hospital, Hsiang et al. (2015), showed that the common primary etiologies for liver cirrhosis were chronic hepatitis B cirrhosis (37.3%), alcoholic liver disease cirrhosis (24.1%), chronic hepatitis C cirrhosis (22.3%), and non-alcoholic fatty liver disease cirrhosis (16.4%).
Hepatic Cirrhosis Market Epidemiological Segmentation
- Hepatic Cirrhosis total prevalent cases
- Hepatic Cirrhosis age-specific cases
- Hepatic Cirrhosis gender-specific cases
- Hepatic Cirrhosis specific cases
Hepatic Cirrhosis Market Outlook
The Hepatic Cirrhosis market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Hepatic Cirrhosis market trends by analyzing the impact of current Hepatic Cirrhosis therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Hepatic Cirrhosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hepatic Cirrhosis market data are presented with relevant tables and graphs to give a clear picture of the market at first sight
According to DelveInsight, the Hepatic Cirrhosis market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Hepatic Cirrhosis Market Landscape
Hepatic Cirrhosis Key Companies
- GalectinTherapeutics
- Cymabay Therapeutics
- And many others
Hepatic Cirrhosis Therapy
- Bela Pectin
- Seladelpar
- And many others
Table of Contents
- Key Insights
- Report Introduction
- Executive Summary of Hepatic Cirrhosis
- Disease Background and Overview
- Epidemiology and patient population
- The United States
- EU 5
- Hepatic Cirrhosis Emerging Therapies
- Hepatic Cirrhosis Market Outlook
- Market Access and Reimbursement of Therapies
- Appendix
- Hepatic Cirrhosis Report Methodology
- DelveInsight Capabilities
- Disclaimer
Click here to read more about Hepatic Cirrhosis Market
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/